Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation

V. J. Nijenhuis, J. Brouwer, R. Delewi, R. S. Hermanides, W. Holvoet, C. L. F. Dubois, P. Frambach, B. De Bruyne, G. K. van Houwelingen, J. A. S. Van der Heyden, P. Tousek, F. van der Kley, I. Buysschaert, C. E. Schotborgh, B. Ferdinande, P. van der Harst, J. Roosen, J. Peper, F. W. F. Thielen, L. VeenstraD. R. P. P. Chan Pin Yin, M. J. Swaans, B. J. W. M. Rensing, A. W. J. van 't Hof, L. Timmers, J. C. Kelder, P. R. Stella, J. Baan, J. M. ten Berg*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1696-1707
Number of pages12
JournalNew England Journal of Medicine
Volume382
Issue number18
DOIs
Publication statusPublished - 30 Apr 2020

Keywords

  • ATRIAL-FIBRILLATION
  • ANTIPLATELET THERAPY
  • 1-YEAR OUTCOMES
  • REPLACEMENT
  • RISK
  • TAVI
  • MANAGEMENT
  • DEFINITIONS
  • GUIDELINES
  • PREDICTORS

Cite this